BAIRD MEDICAL INVESTMENT HOL (BDMD) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:BDMD • KYG0705H1039

0.9204 USD
+0.02 (+1.74%)
At close: Feb 6, 2026
0.92 USD
0 (-0.04%)
After Hours: 2/6/2026, 8:19:13 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to BDMD. BDMD was compared to 186 industry peers in the Health Care Equipment & Supplies industry. While BDMD is still in line with the averages on profitability rating, there are concerns on its financial health. BDMD has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

5

1. Profitability

1.1 Basic Checks

  • In the past year BDMD was profitable.
  • In the past year BDMD has reported a negative cash flow from operations.
  • The reported net income has been mixed in the past 5 years: BDMD reported negative net income in multiple years.
  • BDMD had a negative operating cash flow in each of the past 5 years.
BDMD Yearly Net Income VS EBIT VS OCF VS FCFBDMD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 0 5M -5M 10M 15M

1.2 Ratios

  • Looking at the Return On Assets, with a value of 16.24%, BDMD belongs to the top of the industry, outperforming 96.77% of the companies in the same industry.
  • BDMD has a Return On Equity of 35.14%. This is amongst the best in the industry. BDMD outperforms 99.46% of its industry peers.
  • BDMD has a better Return On Invested Capital (24.25%) than 98.39% of its industry peers.
Industry RankSector Rank
ROA 16.24%
ROE 35.14%
ROIC 24.25%
ROA(3y)11.63%
ROA(5y)N/A
ROE(3y)20.43%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BDMD Yearly ROA, ROE, ROICBDMD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 10 20 30

1.3 Margins

  • With an excellent Profit Margin value of 33.76%, BDMD belongs to the best of the industry, outperforming 98.92% of the companies in the same industry.
  • BDMD has a better Operating Margin (41.35%) than 100.00% of its industry peers.
  • Looking at the Gross Margin, with a value of 88.17%, BDMD belongs to the top of the industry, outperforming 97.31% of the companies in the same industry.
Industry RankSector Rank
OM 41.35%
PM (TTM) 33.76%
GM 88.17%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BDMD Yearly Profit, Operating, Gross MarginsBDMD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. Health

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), BDMD is creating value.
  • BDMD has less shares outstanding than it did 1 year ago.
  • BDMD has a worse debt/assets ratio than last year.
BDMD Yearly Shares OutstandingBDMD Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 5M 10M 15M 20M 25M
BDMD Yearly Total Debt VS Total AssetsBDMD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

  • BDMD has an Altman-Z score of 2.24. This is not the best score and indicates that BDMD is in the grey zone with still only limited risk for bankruptcy at the moment.
  • BDMD has a better Altman-Z score (2.24) than 64.52% of its industry peers.
  • A Debt/Equity ratio of 0.56 indicates that BDMD is somewhat dependend on debt financing.
  • BDMD has a Debt to Equity ratio of 0.56. This is comparable to the rest of the industry: BDMD outperforms 40.32% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.56
Debt/FCF N/A
Altman-Z 2.24
ROIC/WACC2.87
WACC8.44%
BDMD Yearly LT Debt VS Equity VS FCFBDMD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 50M 100M 150M 200M

2.3 Liquidity

  • BDMD has a Current Ratio of 1.71. This is a normal value and indicates that BDMD is financially healthy and should not expect problems in meeting its short term obligations.
  • BDMD has a Current ratio of 1.71. This is in the lower half of the industry: BDMD underperforms 67.20% of its industry peers.
  • A Quick Ratio of 1.67 indicates that BDMD should not have too much problems paying its short term obligations.
  • BDMD has a Quick ratio of 1.67. This is comparable to the rest of the industry: BDMD outperforms 46.24% of its industry peers.
Industry RankSector Rank
Current Ratio 1.71
Quick Ratio 1.67
BDMD Yearly Current Assets VS Current LiabilitesBDMD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 20M 40M 60M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. Growth

3.1 Past

  • BDMD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 18.58%, which is quite good.
  • BDMD shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 17.74%.
EPS 1Y (TTM)18.58%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-356.32%
Revenue 1Y (TTM)17.74%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-39.41%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BDMD Yearly Revenue VS EstimatesBDMD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 10M 20M 30M

More info and screens

Find the best growth stocksShow best growing peers

3

4. Valuation

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 1.92, the valuation of BDMD can be described as very cheap.
  • BDMD's Price/Earnings ratio is rather cheap when compared to the industry. BDMD is cheaper than 100.00% of the companies in the same industry.
  • When comparing the Price/Earnings ratio of BDMD to the average of the S&P500 Index (27.93), we can say BDMD is valued rather cheaply.
Industry RankSector Rank
PE 1.92
Fwd PE N/A
BDMD Price Earnings VS Forward Price EarningsBDMD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, BDMD is valued cheaper than 99.46% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 1.81
BDMD Per share dataBDMD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for BDMD!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

BAIRD MEDICAL INVESTMENT HOL

NASDAQ:BDMD (2/6/2026, 8:19:13 PM)

After market: 0.92 0 (-0.04%)

0.9204

+0.02 (+1.74%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)05-15
Earnings (Next)N/A
Inst Owners1.82%
Inst Owner ChangeN/A
Ins Owners71.59%
Ins Owner ChangeN/A
Market Cap23.53M
Revenue(TTM)37.04M
Net Income(TTM)12.50M
AnalystsN/A
Price TargetN/A
Short Float %872.95%
Short Ratio1.34
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 1.92
Fwd PE N/A
P/S 0.64
P/FCF N/A
P/OCF N/A
P/B 0.66
P/tB 0.66
EV/EBITDA 1.81
EPS(TTM)0.48
EY52.15%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.31
FCFYN/A
OCF(TTM)-0.22
OCFYN/A
SpS1.45
BVpS1.39
TBVpS1.39
PEG (NY)N/A
PEG (5Y)N/A
Graham Number3.88
Profitability
Industry RankSector Rank
ROA 16.24%
ROE 35.14%
ROCE 36.88%
ROIC 24.25%
ROICexc 25.24%
ROICexgc 25.27%
OM 41.35%
PM (TTM) 33.76%
GM 88.17%
FCFM N/A
ROA(3y)11.63%
ROA(5y)N/A
ROE(3y)20.43%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.48
Health
Industry RankSector Rank
Debt/Equity 0.56
Debt/FCF N/A
Debt/EBITDA 1.2
Cap/Depr 210.97%
Cap/Sales 6.52%
Interest Coverage 24.84
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.71
Quick Ratio 1.67
Altman-Z 2.24
F-Score2
WACC8.44%
ROIC/WACC2.87
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)18.58%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-356.32%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)17.74%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-39.41%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y29.11%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-249.14%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-143.28%
OCF growth 3YN/A
OCF growth 5YN/A

BAIRD MEDICAL INVESTMENT HOL / BDMD FAQ

What is the ChartMill fundamental rating of BAIRD MEDICAL INVESTMENT HOL (BDMD) stock?

ChartMill assigns a fundamental rating of 3 / 10 to BDMD.


What is the valuation status of BAIRD MEDICAL INVESTMENT HOL (BDMD) stock?

ChartMill assigns a valuation rating of 3 / 10 to BAIRD MEDICAL INVESTMENT HOL (BDMD). This can be considered as Overvalued.


How profitable is BAIRD MEDICAL INVESTMENT HOL (BDMD) stock?

BAIRD MEDICAL INVESTMENT HOL (BDMD) has a profitability rating of 5 / 10.


What is the valuation of BAIRD MEDICAL INVESTMENT HOL based on its PE and PB ratios?

The Price/Earnings (PE) ratio for BAIRD MEDICAL INVESTMENT HOL (BDMD) is 1.92 and the Price/Book (PB) ratio is 0.66.